Dea No. 2884 en es it fr

Dea No. 2884 Brand names, Dea No. 2884 Analogs

Dea No. 2884 Brand Names Mixture

  • No information avaliable

Dea No. 2884 Chemical_Formula


Dea No. 2884 RX_link

Dea No. 2884 fda sheet

Dea No. 2884 msds (material safety sheet)

Dea_No._2884 MSDS

Dea No. 2884 Synthesis Reference

No information avaliable

Dea No. 2884 Molecular Weight

325.767 g/mol

Dea No. 2884 Melting Point

159 oC

Dea No. 2884 H2O Solubility

40.0 mg/ml

Dea No. 2884 State


Dea No. 2884 LogP


Dea No. 2884 Dosage Forms

Liquid; Solution

Dea No. 2884 Indication

For use in pediatric patients for sedation, anxiolysis, and amnesia prior to diagnostic, therapeutic, or endoscopic procedures or before induction of anesthesia.

Dea No. 2884 Pharmacology

Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the (gamma)-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.

Dea No. 2884 Absorption

Rapidly absorbed after oral administration (absolute bioavailability of the midazolam syrup in pediatric patients is about 36%, and intramuscular is greater than 90%).

Dea No. 2884 side effects and Toxicity

LD50=825 mg/kg (Orally in rats). Signs of overdose include sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma, and deleterious effects on vital signs.

Dea No. 2884 Patient Information

Dea No. 2884 Organisms Affected

Humans and other mammals